A study to investigate safety, tolerability and pharmacokinetics of AZD1446 administered for 4 weeks in elderly healthy volunteers
Study identifier:D1950C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1446, Placebo
Sex
All
Actual Enrollment
97
Study type
Interventional
Age
65 Years - 85 Years
Date
Study Start Date: 01 Oct 2009
Primary Completion Date: 01 Dec 2009
Study Completion Date: 01 Dec 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD1446 Low Low dose of AZD1446 | Drug: AZD1446 Solution, oral, for 4 weeks |
| Experimental: AZD1446 High High dose of AZD1446 | Drug: AZD1446 Solution, oral, for 4 weeks |
| Placebo Comparator: Placebo | - |
Contacts
Investigators
Principal Investigator
Bo Fransson
AstraZeneca R&DClinical Pharmacology Unit CPUTunavägen 22aS-221 87 LundSweden
